At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 275 enrolled
Drug / intervention
CIN-107 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)
In Brief
A Phase 2 clinical trial evaluating CIN-107 and Placebo for Resistant Hypertension. Completed, enrolled 275 participants across 80 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsResistant Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartOct 2020
Primary CompletionJun 2022
TodayJul 2026
First PostedAug 20, 2020
Enrollment StartOct 12, 2020
Primary CompletionJun 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.9 years ago
Interventions
CIN-107drug
CIN-107 tablets by mouth once daily
Placebodrug
placebo tablets by mouth once daily